CLINICAL TRIALS PROFILE FOR DYSPORT

All Clinical Trials for DYSPORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00134810 ↗	Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome	Completed	Ipsen	Phase 2	2005-03-01	The main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder.
NCT00149240 ↗	Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome	Completed	Ipsen	Phase 2	2005-01-01	The main purpose of this study is to determine the effectiveness and safety of one dose of botulinum toxin type A (Dysport) associated with rehabilitation treatment on pain control in patients with a type of back pain called primary myofascial pain syndrome.
NCT00210444 ↗	Efficacy Study of Dysport® in the Treatment of Anal Fissure.	Completed	Ipsen	Phase 2	2003-06-01	To evaluate the effect on healing rates of two different prognostic factors in patients treated with Dysport® for anal fissure: duration of fissure and dose of study drug
NCT00213577 ↗	NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder	Terminated	University Hospital, Rouen	Phase 2	2003-12-01	The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.
NCT00216411 ↗	Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm	Completed	Ipsen	Phase 4	2004-11-01	The main purpose of this study is to assess the effect on Quality of Life of two cycles of Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on spasticity and function will also be measured.
NCT00234507 ↗	Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm	Completed	Ipsen	Phase 2	2003-01-01	The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.
NCT00234546 ↗	Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity	Completed	Ipsen	Phase 4	2003-02-01	The aim of this clinical study is to investigate the efficacy and safety of Dysport® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke.

Clinical Trial Conditions for DYSPORT

Condition Name

Condition Name for DYSPORT
Intervention	Trials
Cervical Dystonia	9
Cerebral Palsy	6
Muscle Spasticity	5
Overactive Bladder	5

Condition MeSH

Condition MeSH for DYSPORT
Intervention	Trials
Muscle Spasticity	13
Dystonic Disorders	10
Dystonia	10
Torticollis	9

Clinical Trial Locations for DYSPORT

Trials by Country

Trials by Country for DYSPORT
Location	Trials
United States	214
Poland	14
France	14
Czech Republic	12
Germany	11

Trials by US State

Trials by US State for DYSPORT
Location	Trials
Florida	17
California	17
New York	15
Texas	14
Pennsylvania	12

Clinical Trial Progress for DYSPORT

Clinical Trial Phase

Clinical Trial Phase for DYSPORT
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	27
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for DYSPORT
Clinical Trial Phase	Trials
Completed	60
Terminated	11
Not yet recruiting	6

Clinical Trial Sponsors for DYSPORT

Sponsor Name

Sponsor Name for DYSPORT
Sponsor	Trials
Ipsen	44
Brazilan Center for Studies in Dermatology	4
Galderma R&D	4

Sponsor Type

Sponsor Type for DYSPORT
Sponsor	Trials
Industry	59
Other	55
U.S. Fed	1